+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Allergic Conjunctivitis Market By Drug Class, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031- Product Image
Allergic Conjunctivitis Market By Drug Class, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031- Product Image
Sale

Allergic Conjunctivitis Market By Drug Class, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 303 Pages
  • July 2022
  • Region: Global
  • Allied Market Research
  • ID: 5671070
UP TO OFF until Jan 30th 2025
Description Jump to:
The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28%% from 2022 to 2031.

An allergic reaction to things such as pollen, mold, or spores can result in an eye inflammation known as allergic conjunctivitis. The conjunctiva is a membrane that covers the interior of the eyelids and the surface of the eyeball. Allergens can irritate the conjunctiva, especially during the hay fever season. Conjunctivitis due to an allergy is extremely prevalent. It is a response by individual’s body to chemicals that it seems to be potentially dangerous.

Conjunctivitis caused by allergens is one of the most commonly occurring allergies. According to the Asthma and Allergy Foundation of America, allergies run in families and impact 30% of adults and 40% of children. Common signs of allergic conjunctivitis include red, watery, burning, and itchy eyes. It's also possible to have puffy eyes when one first wake up in the morning.

The major factors that drive the growth of the allergic conjunctivitis market are increase in patient population suffering from ocular allergies. According to National Centre of medicine allergic conjunctivitis or conjunctival symptoms are present in 30-71% of patients with allergic rhinitis as many people are suffering from allergic conjunctivitis demand for drugs increases. In addition, many key market players are focusing on R&D activities to develop new drugs for the treatment of ocular allergies is a key trend of the market, which is expected to fuel the growth in the forecast period.

Furthermore, poor hygienic practices such as touching eyes with unclean hands, using contaminated makeup & lotions causes ocular allergy, which is anticipated to drive the market growth in the near future. Rise in prevalence of sexually transmitted diseases tends to drive the market growth. The most prevalent STIs are chlamydia and gonorrhoea, and both can result in conjunctivitis. Either directly through sexual fluids like semen or when infected individuals rub their eyes after contacting infected genital areas, which are the two ways the illness enters the eye. Thus, such high number of cases are expected to boost the allergic conjunctivitis procedures.

However, unfavorable reimbursements scenarios and lack of awareness of ocular allergies are expected to hinder the growth of the market. Conversely, rapid rise in urbanization leads to more exposure to chemicals and pollutants in both developed and developing countries, which is expected to provide a great opportunity for the investors to invest in the market.

The global allergic conjunctivitis market is segmented on the basis of drug class, disease type, distribution channel, and region. On the basis of drug class, the market is categorized into antihistamines & mast cell, corticosteroids, and others. By disease type, it is divided into seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC). The seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) each are further sub segmented by age group into adult and pediatric. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., Novartis AG, Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd andTeva Pharmaceutical Industries Ltd.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergic conjunctivitis market analysis from 2021 to 2031 to identify the prevailing allergic conjunctivitis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the allergic conjunctivitis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global allergic conjunctivitis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Antihistamines Mast Cell Stabilizers
  • Corticosteroids
  • Others

By Disease Type

  • Seasonal Allergic Conjunctivitis (SAC)
  • Perennial Allergic Conjunctivitis (PAC)

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores Retail Pharmacies
  • Online providers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • AbbVie Inc.
  • Ajanta Pharma Limited
  • Akron Operating Company LLC
  • Alembic Pharmaceuticals Ltd.
  • Bausch Health Companies Inc.
  • Cipla Ltd
  • Grevis Pharmaceutical Private Limited
  • Indoco Remedies Ltd.
  • Jabs Biotech Pvt. Ltd.
  • JAWA Pharmaceuticals Pvt. Ltd.
  • Johnson and Johnson
  • Novartis AG
  • Ocular Therapeutics, Inc.
  • Santen Pharmaceuticals Co. Ltd.
  • Spectra Vision Care Pvt. Ltd.
  • Sun Pharmaceuticals Industries Ltd
  • Teva Pharmaceutical Industries Ltd.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Antihistamines & Mast Cell Stabilizers
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Corticosteroids
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Seasonal Allergic Conjunctivitis (SAC)
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Perennial Allergic Conjunctivitis (PAC)
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug stores & Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: ALLERGIC CONJUNCTIVITIS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Disease Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Disease Type
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Disease Type
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Disease Type
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Disease Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Disease Type
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Disease Type
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Disease Type
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Disease Type
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Disease Type
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Disease Type
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Disease Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Disease Type
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Disease Type
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Disease Type
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Disease Type
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Disease Type
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Disease Type
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Disease Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Disease Type
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Disease Type
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Disease Type
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Disease Type
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Ajanta Pharma Limited
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Akron Operating Company LLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Alembic Pharmaceuticals Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Bausch Health Companies Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Cipla Ltd
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Grevis Pharmaceutical Private Limited
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Indoco Remedies Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Jabs Biotech Pvt. Ltd.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 JAWA Pharmaceuticals Pvt. Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Johnson and Johnson
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Novartis AG
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Ocular Therapeutics, Inc.
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Santen Pharmaceuticals Co. Ltd.
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Spectra Vision Care Pvt. Ltd.
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Sun Pharmaceuticals Industries Ltd
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Teva Pharmaceutical Industries Ltd.
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
List of Tables
Table 1. Global Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 2. Unilateral Biportal Endoscopy Market Size, for Endoscope, by Region, 2021-2031 ($Million)
Table 3. Unilateral Biportal Endoscopy Market for Endoscope by Country, 2021-2031 ($Million)
Table 4. Unilateral Biportal Endoscopy Market Size, for Accessory Devices, by Region, 2021-2031 ($Million)
Table 5. Unilateral Biportal Endoscopy Market for Accessory Devices by Country, 2021-2031 ($Million)
Table 6. Global Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 7. Unilateral Biportal Endoscopy Market Size, for Herniated Discs, by Region, 2021-2031 ($Million)
Table 8. Unilateral Biportal Endoscopy Market for Herniated Discs by Country, 2021-2031 ($Million)
Table 9. Unilateral Biportal Endoscopy Market Size, for Spinal Stenosis, by Region, 2021-2031 ($Million)
Table 10. Unilateral Biportal Endoscopy Market for Spinal Stenosis by Country, 2021-2031 ($Million)
Table 11. Unilateral Biportal Endoscopy Market Size, for Others, by Region, 2021-2031 ($Million)
Table 12. Unilateral Biportal Endoscopy Market for Others by Country, 2021-2031 ($Million)
Table 13. Global Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 14. Unilateral Biportal Endoscopy Market Size, for Hospitals, by Region, 2021-2031 ($Million)
Table 15. Unilateral Biportal Endoscopy Market for Hospitals by Country, 2021-2031 ($Million)
Table 16. Unilateral Biportal Endoscopy Market Size, for Ambulatory Surgical Centers, by Region, 2021-2031 ($Million)
Table 17. Unilateral Biportal Endoscopy Market for Ambulatory Surgical Centers by Country, 2021-2031 ($Million)
Table 18. Unilateral Biportal Endoscopy Market, by Region, 2021-2031 ($Million)
Table 19. North America Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 20. North America Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 21. North America Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 22. North America Unilateral Biportal Endoscopy Market, by Country, 2021-2031 ($Million)
Table 23. U.S. Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 24. U.S. Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 25. U.S. Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 26. Canada Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 27. Canada Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 28. Canada Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 29. Mexico Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 30. Mexico Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 31. Mexico Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 32. Europe Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 33. Europe Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 34. Europe Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 35. Europe Unilateral Biportal Endoscopy Market, by Country, 2021-2031 ($Million)
Table 36. Germany Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 37. Germany Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 38. Germany Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 39. France Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 40. France Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 41. France Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 42. U.K. Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 43. U.K. Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 44. U.K. Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 45. Italy Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 46. Italy Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 47. Italy Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 48. Spain Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 49. Spain Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 50. Spain Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 51. Rest of Europe Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 52. Rest of Europe Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 53. Rest of Europe Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 54. Asia-Pacific Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 55. Asia-Pacific Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 56. Asia-Pacific Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 57. Asia-Pacific Unilateral Biportal Endoscopy Market, by Country, 2021-2031 ($Million)
Table 58. Japan Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 59. Japan Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 60. Japan Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 61. China Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 62. China Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 63. China Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 64. Australia Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 65. Australia Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 66. Australia Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 67. India Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 68. India Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 69. India Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 70. South Korea Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 71. South Korea Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 72. South Korea Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 73. Rest of Asia-Pacific Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 74. Rest of Asia-Pacific Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 75. Rest of Asia-Pacific Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 76. LAMEA Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 77. LAMEA Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 78. LAMEA Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 79. LAMEA Unilateral Biportal Endoscopy Market, by Country, 2021-2031 ($Million)
Table 80. Brazil Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 81. Brazil Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 82. Brazil Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 83. South Africa, Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 84. South Africa, Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 85. South Africa, Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 86. Saudi Arabia Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 87. Saudi Arabia Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 88. Saudi Arabia Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 89. Rest of LAMEA Unilateral Biportal Endoscopy Market, by Product Type, 2021-2031 ($Million)
Table 90. Rest of LAMEA Unilateral Biportal Endoscopy Market, by Indication, 2021-2031 ($Million)
Table 91. Rest of LAMEA Unilateral Biportal Endoscopy Market, by End-user, 2021-2031 ($Million)
Table 92. Endovision Co. Ltd.: Company Snapshot
Table 93. Endovision Co. Ltd.: Operating Segments
Table 94. Endovision Co. Ltd.: Product Portfolio
Table 95. Endovision Co. Ltd.: Net Sales
Table 96. Endovision Co. Ltd.: Key Stratergies
Table 97. Jiangsu Bonss Medical Technology Co. Ltd.: Company Snapshot
Table 98. Jiangsu Bonss Medical Technology Co. Ltd.: Operating Segments
Table 99. Jiangsu Bonss Medical Technology Co. Ltd.: Product Portfolio
Table 100. Jiangsu Bonss Medical Technology Co. Ltd.: Net Sales
Table 101. Jiangsu Bonss Medical Technology Co. Ltd.: Key Stratergies
Table 102. Joimax GmbH: Company Snapshot
Table 103. Joimax GmbH: Operating Segments
Table 104. Joimax GmbH: Product Portfolio
Table 105. Joimax GmbH: Net Sales
Table 106. Joimax GmbH: Key Stratergies
Table 107. Karl Storz: Company Snapshot
Table 108. Karl Storz: Operating Segments
Table 109. Karl Storz: Product Portfolio
Table 110. Karl Storz: Net Sales
Table 111. Karl Storz: Key Stratergies
Table 112. Kinetix Lifesciences: Company Snapshot
Table 113. Kinetix Lifesciences: Operating Segments
Table 114. Kinetix Lifesciences: Product Portfolio
Table 115. Kinetix Lifesciences: Net Sales
Table 116. Kinetix Lifesciences: Key Stratergies
Table 117. Maxer Endoscopy GmbH: Company Snapshot
Table 118. Maxer Endoscopy GmbH: Operating Segments
Table 119. Maxer Endoscopy GmbH: Product Portfolio
Table 120. Maxer Endoscopy GmbH: Net Sales
Table 121. Maxer Endoscopy GmbH: Key Stratergies
Table 122. Richard Wolf: Company Snapshot
Table 123. Richard Wolf: Operating Segments
Table 124. Richard Wolf: Product Portfolio
Table 125. Richard Wolf: Net Sales
Table 126. Richard Wolf: Key Stratergies
Table 127. Smith & Nephew: Company Snapshot
Table 128. Smith & Nephew: Operating Segments
Table 129. Smith & Nephew: Product Portfolio
Table 130. Smith & Nephew: Net Sales
Table 131. Smith & Nephew: Key Stratergies
Table 132. Stryker Corporation: Company Snapshot
Table 133. Stryker Corporation: Operating Segments
Table 134. Stryker Corporation: Product Portfolio
Table 135. Stryker Corporation: Net Sales
Table 136. Stryker Corporation: Key Stratergies
Table 137. Conmed Corporation: Company Snapshot
Table 138. Conmed Corporation: Operating Segments
Table 139. Conmed Corporation: Product Portfolio
Table 140. Conmed Corporation: Net Sales
Table 141. Conmed Corporation: Key Stratergies
List of Figures
Figure 1. Allergic Conjunctivitis Market Segmentation
Figure 2. Allergic Conjunctivitis Market,2021-2031
Figure 3. Allergic Conjunctivitis Market,2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Allergic Conjunctivitis Market:Drivers, Restraints and Opportunities
Figure 12. Allergic Conjunctivitis Market,By Drug Class,2021(%)
Figure 13. Comparative Share Analysis of Antihistamines & Mast Cell Stabilizers Allergic Conjunctivitis Market,2021-2031(%)
Figure 14. Comparative Share Analysis of Corticosteroids Allergic Conjunctivitis Market,2021-2031(%)
Figure 15. Comparative Share Analysis of Others Allergic Conjunctivitis Market,2021-2031(%)
Figure 16. Allergic Conjunctivitis Market,By Disease Type,2021(%)
Figure 17. Comparative Share Analysis of Seasonal Allergic Conjunctivitis (Sac) Allergic Conjunctivitis Market,2021-2031(%)
Figure 18. Comparative Share Analysis of Perennial Allergic Conjunctivitis (Pac) Allergic Conjunctivitis Market,2021-2031(%)
Figure 19. Allergic Conjunctivitis Market,By Distribution Channel,2021(%)
Figure 20. Comparative Share Analysis of Hospital Pharmacies Allergic Conjunctivitis Market,2021-2031(%)
Figure 21. Comparative Share Analysis of Drug Stores & Retail Pharmacies Allergic Conjunctivitis Market,2021-2031(%)
Figure 22. Comparative Share Analysis of Online Providers Allergic Conjunctivitis Market,2021-2031(%)
Figure 23. Allergic Conjunctivitis Market by Region,2021
Figure 24. U.S. Allergic Conjunctivitis Market,2021-2031($Million)
Figure 25. Canada Allergic Conjunctivitis Market,2021-2031($Million)
Figure 26. Mexico Allergic Conjunctivitis Market,2021-2031($Million)
Figure 27. Germany Allergic Conjunctivitis Market,2021-2031($Million)
Figure 28. France Allergic Conjunctivitis Market,2021-2031($Million)
Figure 29. Uk Allergic Conjunctivitis Market,2021-2031($Million)
Figure 30. Italy Allergic Conjunctivitis Market,2021-2031($Million)
Figure 31. Spain Allergic Conjunctivitis Market,2021-2031($Million)
Figure 32. Rest of Europe Allergic Conjunctivitis Market,2021-2031($Million)
Figure 33. Japan Allergic Conjunctivitis Market,2021-2031($Million)
Figure 34. China Allergic Conjunctivitis Market,2021-2031($Million)
Figure 35. Australia Allergic Conjunctivitis Market,2021-2031($Million)
Figure 36. India Allergic Conjunctivitis Market,2021-2031($Million)
Figure 37. South Korea Allergic Conjunctivitis Market,2021-2031($Million)
Figure 38. Rest of Asia-Pacific Allergic Conjunctivitis Market,2021-2031($Million)
Figure 39. Brazil Allergic Conjunctivitis Market,2021-2031($Million)
Figure 40. Saudi Arabia Allergic Conjunctivitis Market,2021-2031($Million)
Figure 41. South Africa Allergic Conjunctivitis Market,2021-2031($Million)
Figure 42. Rest of LAMEA Allergic Conjunctivitis Market,2021-2031($Million)
Figure 43. Top Winning Strategies, by Year
Figure 44. Top Winning Strategies, by Development
Figure 45. Top Winning Strategies, by Company
Figure 46. Product Mapping of Top 10 Players
Figure 47. Competitive Dashboard
Figure 48. Competitive Heatmap of Top 10 Key Players
Figure 49. Abbvie Inc..: Net Sales ,($Million)
Figure 50. Ajanta Pharma Limited.: Net Sales ,($Million)
Figure 51. Akron Operating Company LLC.: Net Sales ,($Million)
Figure 52. Alembic Pharmaceuticals Ltd..: Net Sales ,($Million)
Figure 53. Bausch Health Companies Inc..: Net Sales ,($Million)
Figure 54. Cipla Ltd.: Net Sales ,($Million)
Figure 55. Grevis Pharmaceutical Private Limited.: Net Sales ,($Million)
Figure 56. Indoco Remedies Ltd..: Net Sales ,($Million)
Figure 57. Jabs Biotech Pvt. Ltd..: Net Sales ,($Million)
Figure 58. Jawa Pharmaceuticals Pvt. Ltd..: Net Sales ,($Million)
Figure 59. Johnson and Johnson.: Net Sales ,($Million)
Figure 60. Novartis AG.: Net Sales ,($Million)
Figure 61. Ocular Therapeutics, Inc..: Net Sales ,($Million)
Figure 62. Santen Pharmaceuticals Co. Ltd..: Net Sales ,($Million)
Figure 63. Spectra Vision Care Pvt. Ltd..: Net Sales ,($Million)
Figure 64. Sun Pharmaceuticals Industries Ltd.: Net Sales ,($Million)
Figure 65. Teva Pharmaceutical Industries Ltd..: Net Sales ,($Million)

Executive Summary

According to the report, titled, “Allergic Conjunctivitis Market," the allergic conjunctivitis market was valued at $1.9 billion in 2021, and is estimated to reach $3 billion by 2031, growing at a CAGR of 4.3% from 2022 to 2031.

The term "allergic conjunctivitis" refers to a common type of allergic eye condition in which the conjunctiva of the eye becomes inflamed as a result of an allergic reaction. A sizable population is affected by this disease, yet both patients and medical staff frequently overlook it or fail to properly diagnose it. When an allergen comes into touch with the eyes of allergic people are affected by allergic conjunctivitis. Histamine is released in response to the allergen. Typically, this causes the conjunctivae to itch, get red, burn, or tear. These are the delicate membranes that cover the exposed area of the eyes and the eyelids.

Allergic conjunctivitis can be seasonal or perennial. The seasonal type is far more prevalent. It has to do with coming into contact with allergens in the air, including mold or pollen from grass, trees, and weeds. The perennial type lasts all year and is typically brought on by molds, animal dander, or dusts.

The rise in the number of patients is one of the main drivers of the allergic conjunctivitis market's expansion. Morever, allergic conjunctivitis market trends are anticipated to fuel growth in the forecast period is that several major market players are concentrating on R&D operations to create new medications for the treatment of ocular allergies to fulfill the demand of the growing patient pool. The use of contaminated makeup and lotions, rubbing the eyes with dirty hands, and other poor hygiene habits contribute to ocular allergies, which are expected for the allergic conjunctivitis market growth. The increase in the prevalence of STDs typically fuels market expansion. Chlamydia and gonorrhea, the two STIs that are most common, can both cause conjunctivitis.

The lack of awareness about ocular allergies is anticipated to impede market expansion, notwithstanding challenging reimbursements conditions. In contrast, the rapid increase in urbanization that causes increased exposure to chemicals and pollutants in both developed and emerging countries is anticipated to offer enormous investment opportunities in allergic conjunctivitis industry.

By drug class, the market is segmented into antihistamines & mast cell stabilizers, corticosteroids, and others. The antihistamines & mast cell stabilizers segment dominated the allergic conjunctivitis market size in 2021, accounting $1171.22million and also expected to witness highest CAGR of 4.81% during the forecast period, owing to new product launches by various key market players.

Depending on disease type, the market is divided into seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) The seasonal allergic conjunctivitis (SAC) segment dominated the market in 2021, with $1264.98million and is also expected to witness highest CAGR of4.66% during the forecast period, owing to prevalence of incidence of seasonal allergic conjunctivitis.

Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, with $1174.69million owing to its presence in commercial areas of the community. The online providers segment is expected to witness highest CAGR of 3.85%during the forecast period, owing to popular medium for purchase of medicines
North America accounted for a majority of the global allergic conjunctivitis market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in allergic conjunctivitis techniques, R & D of advanced drugs for allergic conjunctivitis, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in patient population, development of healthcare infrastructure and increase in investments projects in the region.

Key Findings of the Study

  • By drug class, the antihistamines & mast cell stabilizers segment was the highest contributor to the market in 2021.
  • By disease type, the seasonal allergic conjunctivitis segment was the highest contributor to the market in 2021.
  • Depending on distribution channel, the drug store & retail pharmacies segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.
  • Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

  • Abbvie Inc.
  • Ajanta Pharma Limited
  • Akron Operating Company LLC
  • Alembic Pharmaceuticals Ltd.
  • Bausch Health Companies Inc.
  • Cipla Ltd
  • Grevis Pharmaceutical Private Limited
  • Indoco Remedies Ltd.
  • Jabs Biotech Pvt. Ltd.
  • Jawa Pharmaceuticals Pvt. Ltd.
  • Johnson and Johnson
  • Novartis AG
  • Ocular Therapeutics, Inc.
  • Santen Pharmaceuticals Co. Ltd.
  • Spectra Vision Care Pvt. Ltd.
  • Sun Pharmaceuticals Industries Ltd
  • Teva Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages303
PublishedJuly 2022
Forecast Period2021 - 2031
Estimated Market Value ( USD ) in 2021 $ 1937.99 million
Forecasted Market Value ( USD ) by 2031 $ 2954.2 million
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Global Allergic Conjunctivitis Market Report by Disease Type, Drug class, Distribution Channel, Countries and Company Analysis, 2024-2032 - Product Image

Global Allergic Conjunctivitis Market Report by Disease Type, Drug class, Distribution Channel, Countries and Company Analysis, 2024-2032

  • Report
  • 200 Pages
  • Global
From
Allergic Conjunctivitis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Allergic Conjunctivitis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 85 Pages
  • Global
From
Allergic Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Allergic Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 136 Pages
  • Global
From
Allergic Rhino-Conjunctivitis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Allergic Rhino-Conjunctivitis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Conjunctivitis Treatment Market Size, Share & Trends Analysis Report By Disease Type, By Drug Class (Anti-allergic, Antiviral, Artificial Tears, and Antibiotics), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030 - Product Image

Conjunctivitis Treatment Market Size, Share & Trends Analysis Report By Disease Type, By Drug Class (Anti-allergic, Antiviral, Artificial Tears, and Antibiotics), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • 232 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.